4.5 Article

Upregulation of MMP-2 by HMGA1 Promotes Transformation in Undifferentiated, Large-Cell Lung Cancer

期刊

MOLECULAR CANCER RESEARCH
卷 7, 期 11, 页码 1803-1812

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-08-0336

关键词

-

资金

  1. American Cancer Society [1R01CA092339]
  2. Leukemia & Lymphoma Scholar Award [1694-06]
  3. Alex's Lemonade Stand Foundation
  4. Maryland Stein Cell Research Fund
  5. Gynecologic Cancer Foundation
  6. Prevent Cancer Foundation
  7. Flight Attendant Medical Research Institution
  8. NIH [T32]
  9. VA Merit Review Grant

向作者/读者索取更多资源

Although lung cancer is the leading cause of cancer death worldwide, the precise molecular mechanisms that give rise to lung cancer are incompletely understood. Here, we show that HMGA1 is an important oncogene that drives transformation in undifferentiated, large-cell carcinoma. First, we show that the HMGA1 gene is overexpressed in lung cancer cell lines and primary human lung tumors. Forced overexpression of HMGA1 induces a transformed phenotype with anchorage-independent cell growth in cultured lung cells derived from normal tissue. Conversely, inhibiting HMGA1 expression blocks anchorage-independent cell growth in the H1299 metastatic, undifferentiated, large-cell human lung carcinoma cells. We also show that the matrix metalloproteinase-2 (MMP-2) gene is a downstream target upregulated by HMGA1 in large-cell carcinoma cells. In chromatin immunoprecipitation experiments, HMGA1 binds directly to the MMP-2 promoter in vivo in large-cell lung cancer cells, but not in squamous cell carcinoma cells. In large-cell carcinoma cell lines, there is a significant, positive correlation between HMGA1 and MMP-2 mRNA. Moreover, interfering with MMP-2 expression blocks anchorage-independent cell growth in H1299 large-cell carcinoma cells, indicating that the HMGA1-MMP-2 pathway is required for this transformation phenotype in these cells. Blocking MMP-2 expression also inhibits migration and invasion in the H1299 large-cell carcinoma cells. Our findings suggest an important role for MMP-2 in transformation mediated by HMGA1 in large-cell, undifferentiated lung carcinoma and support the development of strategies to target this pathway in selected tumors. (Mol Cancer Res 2009;7(11):1803-12)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

Paul K. Paik, Pang-Dian Fan, Besnik Qeriqi, Azadeh Namakydoust, Bobby Daly, Linda Ahn, Rachel Kim, Andrew Plodkowski, Ai Ni, Jason Chang, Rachel Fanaroff, Marc Ladanyi, Elisa de Stanchina, Charles M. Rudin

Summary: Increased understanding of the mutational landscape of squamous cell lung cancers (LUSCs) has not resulted in effective targeted therapies. This study investigates the potential of TORC1/2 inhibitor TAK-228 in NSCLC models with NRF2-activating alterations and reports positive outcomes in a phase 2 clinical trial. TAK-228 shows promising single-agent activity in LUSC patients with NRF2 activation and highlights the importance of targeting metabolism in NSCLC.

JOURNAL OF THORACIC ONCOLOGY (2023)

Review Oncology

Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies

Kenta Kawasaki, Natasha Rekhtman, Alvaro Quintanal-Villalonga, Charles M. Rudin

Summary: The review provides a comprehensive overview of the current understanding of NENs in the gastrointestinal system and lung from both clinical and biological perspectives. The authors discuss the commonalities and organ-specific differences of NENs and advocate for a tissue-agnostic approach to drug development, in order to improve patient care by accelerating research across different disease entities.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Article Oncology

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

Noura J. Choudhury, Antonio Marra, Jane S. Y. Sui, Jessica Flynn, Soo-Ryum Yang, Christina J. Falcon, Pier Selenica, Adam J. Schoenfeld, Natasha Rekhtman, Daniel Gomez, Michael F. Berger, Marc Ladanyi, Maria Arcila, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Glenn Heller, Jorge S. Reis-Filho, Helena A. Yu

Summary: The study explores the potential of identifying and intervening on molecular markers associated with therapeutic resistance to improve patient outcomes in metastatic EGFR-mutant lung cancer treated with first-line osimertinib. Baseline atypical EGFR and concurrent TP53/RB1 alterations are associated with shorter progression-free survival on first-line osimertinib. Tissue-based genomic analysis allows for treatment adaptation based on identified mechanisms of resistance at the time of progression, leading to improved postprogression survival.

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Oncology

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Charles M. Rudin, Hardev S. Pandha, Matthew Zibelman, Wallace L. Akerley, Kevin J. Harrington, Daphne Day, Andrew G. Hill, Steven J. O'Day, Timothy D. Clay, Gavin M. Wright, Ross R. Jennens, David E. Gerber, Jonathan E. Rosenberg, Christy Ralph, David C. Campbell, Brendan D. Curti, Jaime R. Merchan, Yixin Ren, Emmett Schmidt, Lisa Guttman, Sumati Gupta

Summary: This study evaluated the efficacy and safety of V937 combined with pembrolizumab in patients with advanced solid tumors. The results showed that the combination therapy had a manageable safety profile, but did not achieve greater efficacy than pembrolizumab monotherapy in non-small cell lung cancer and urothelial cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Editorial Material Oncology

Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?

Salomon Tendler, Charles M. Rudin

JOURNAL OF CLINICAL ONCOLOGY (2023)

Review Oncology

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

Charles M. M. Rudin, Martin Reck, Melissa L. L. Johnson, Fiona Blackhall, Christine L. L. Hann, James Chih-Hsin Yang, Julie M. M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz-Ares

Summary: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine carcinoma with limited treatment options. DLL3, a Notch inhibitory ligand, is overexpressed on SCLC cells, making it an attractive therapeutic target. This article discusses the clinical experience with a DLL3-targeting antibody-drug conjugate called Rova-T, as well as other DLL3-targeting agents currently in development, including T-cell engager molecules and CAR T-cell therapy. The challenges and opportunities for DLL3-targeting therapies, such as using DLL3 as a biomarker and exploring combinatorial approaches, are also discussed.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Article Oncology

Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation

Charles M. Rudin, David Balli, W. Victoria Lai, Allison L. Richards, Evelyn Nguyen, Jacklynn Egger, Noura J. Choudhury, Triparna Sen, Andrew Chow, John T. Poirier, William J. Geese, Matthew D. Hellmann, Ann Forslund

Summary: A study found that antigen presentation machinery signature and infiltrating CD8 T cells were correlated with survival in SCLC patients treated with nivolumab, suggesting their potential as biomarkers for predicting immunotherapy efficacy. The study also identified the association between durable benefit from immunotherapy and antigen processing and presentation.

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Immunology

Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies

Ariella Glasner, Samuel A. Rose, Roshan Sharma, Herman Gudjonson, Tinyi Chu, Jesse A. Green, Sham Rampersaud, Izabella K. Valdez, Emma S. Andretta, Bahawar S. Dhillon, Michail Schizas, Stanislav Dikiy, Alejandra Mendoza, Wei Hu, Zhong-Min Wang, Ojasvi Chaudhary, Tianhao Xu, Linas Mazutis, Gabrielle Rizzuto, Alvaro Quintanal-Villalonga, Parvathy Manoj, Elisa de Stanchina, Charles M. Rudin, Dana Pe'er, Alexander Y. Rudensky

Summary: Traditional roles of regulatory T (T-reg) cells as suppressors of antigen presenting cells and effector T cells have expanded to include tissue maintenance functions, suggesting a broader regulatory role than previously thought. In lung cancer and injury-induced inflammation, T-reg cell depletion led to changes in gene expression in fibroblasts, endothelial and myeloid cells, involving VEGF and CCR2 signaling. Combined T-reg cell depletion and short-term VEGF blockade showed improved control of PD-1 blockade-resistant lung adenocarcinoma progression, highlighting the potential of combination therapies for solid organ cancers.

NATURE IMMUNOLOGY (2023)

Article Biochemistry & Molecular Biology

NBBC: a non-B DNA burden explorer in cancer

Qi Xu, Jeanne Kowalski

Summary: Alternate forms of DNA, such as Z-DNA, G-quadruplex, and triplex, have shown potential roles in cancer development. Non-B DNA-forming sequences have been found to induce genetic instability in human cancer genomes, implicating their involvement in cancer and other genetic diseases. However, existing non-B prediction tools and databases lack the capability to analyze and visualize non-B data in a cancer context. In this study, we present NBBC, a non-B DNA burden explorer in cancer, which provides analysis and visualization for non-B DNA forming motifs. We introduce the concept of 'non-B burden' as a metric to summarize the prevalence of non-B DNA motifs at different levels. With the non-B burden metric, we develop two analysis modules within a cancer context, aiming to explore both gene- and motif-level heterogeneity of non-B DNA. NBBC is designed as a novel analysis and visualization platform guided by non-B burden as a marker.

NUCLEIC ACIDS RESEARCH (2023)

Editorial Material Oncology

Breathing room - focusing on the 'other' lung cancer

Charles M. Rudin

NATURE CANCER (2023)

Article Oncology

De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways

Subhamoy Chakraborty, Charles Coleman, Parvathy Manoj, Deniz Demircioglu, Nisargbhai Shah, Elisa de Stanchina, Charles M. Rudin, Dan Hasson, Triparna Sen

Summary: Lurbinectedin significantly reduces cell viability in most SCLC models, with the best response observed in POU2F3-driven SCLC cells. We also found that lurbinectedin, either as a single agent or in combination with osimertinib, shows an appreciable antitumor response in EGFR-mutant lung adenocarcinoma models with histologic transformation to SCLC. Transcriptomic analysis revealed the induction of apoptosis, repression of epithelial-mesenchymal transition, and modulation of PI3K/AKT, NOTCH signaling associated with lurbinectedin response in both de novo and transformed SCLC models.

CLINICAL CANCER RESEARCH (2023)

Article Genetics & Heredity

Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers

Jaspreet Kaur, Darshan S. Chandrashekar, Zsuzsanna Varga, Bettina Sobottka, Emiel Janssen, Khanjan Gandhi, Jeanne Kowalski, Umay Kiraz, Sooryanarayana Varambally, Ritu Aneja

Summary: This study investigated the genetic profile of triple-negative breast cancer (TNBC) through whole-exome sequencing (WES) analysis. The results showed similar mutational features between primary tumors and recurrent tumors, suggesting that genomic features may be retained during local recurrence.
Article Multidisciplinary Sciences

Article myCMIE: My cancer molecular information exchange

Qi Xu, Jeanne Kowalski

Summary: Molecular profiling reports (MPRs) are crucial for cancer treatment decisions, but synthesizing the complex information contained within them is challenging. Xu and Kowalski developed myCMIE, a web application that provides a patient-centric information system for exchanging molecular profiles and facilitating context-informed treatment options. myCMIE uses interactive digital-twin communities and visualizations to promote discussions among diverse stakeholders in healthcare.

ISCIENCE (2023)

Article Oncology

Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade

Joy A. Pai, Matthew D. Hellmann, Jennifer L. Sauter, Marissa Mattar, Hira Rizvi, Hyung Jun Woo, Nisargbhai Shah, Evelyn M. Nguyen, Fathema Z. Uddin, Alvaro Quintanal-Villalonga, Joseph M. Chan, Parvathy Manoj, Viola Allaj, Marina K. Baine, Umesh K. Bhanot, Mala Jain, Irina Linkov, Fanli Meng, David Brown, Jamie E. Chaft, Andrew J. Plodkowski, Mathieu Gigoux, Helen H. Won, Triparna Sen, Daniel K. Wells, Mark T. A. Donoghue, Elisa de Stanchina, Jedd D. Wolchok, Brian Loomis, Taha Merghoub, Charles M. Rudin, Andrew Chow, Ansuman T. Satpathy

Summary: Paired scRNA/TCR-seq analysis of T cells from NSCLC patients after ICB reveals clonally linked TFH and tumor-specific CD8+ T cells in tumor draining LNs. Exhausted CD8+ T cells, Treg, and TFH cells show progressive exhaustion trajectories with proximity to the tumor microenvironment. Longitudinal tracking demonstrates the persistence of tumor-specific T cell clones in peripheral blood for years after ICB therapy.

CANCER CELL (2023)

Article Medicine, Research & Experimental

IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey, Andrea Lopez, Metamia Ciampricotti, Charles M. Rudin, Renier J. Brentjens

Summary: This study developed a chimeric antigen receptor (CAR) against DLL3 and demonstrated its antitumor efficacy in xenograft and murine SCLC models. CAR T cell expression of IL-18 enhanced the potency of DLL3-targeting CAR T cell therapy and increased the activation of CAR T cells and tumor-infiltrating lymphocytes. Human IL-18-secreting anti-DLL3 CAR T cells showed durable responses in multiple SCLC models, and this effect could be further enhanced with anti-PD-1 blockade.

JOURNAL OF CLINICAL INVESTIGATION (2023)

暂无数据